Higher expression of IL-1 receptor (IL1R1 and IL1RAP) is associated with increased airway neutrophils Background: Various clinical, biologic, or physiologic markers of asthma have been used to identify patient clusters and potential targets for therapy. However, these identifiers frequently overlap among the different asthma groups. For instance, both eosinophil and neutrophil counts are often increased in the airways of asthmatic patients despite their typical association with type 2 and type 17 immune response, respectively. Objectives: We sought to determine whether inflammatory gene expression is related to patterns of airway inflammation and lung function and identify molecular markers for neutrophilic asthma. Methods: Expression levels of 17 genes characterizing type 1, type 2, and type 17 lymphocytes were measured in sputum samples from 48 participants with asthma. The relationships between gene expression levels and sputum cell differentials or measures of pulmonary function were examined by using partial least squares regression. Results: Gene expression levels were strongly associated with cell differentials, explaining 71% of variation in eosinophil counts and 64% of variation in neutrophil counts. The 3 genes with the strongest relationships to sputum neutrophil counts were IL1R1 (standardized regression coefficient [b] 5 10.27, P 5 .005), IL1RAP (b 5 10.32, P 5 .0004), and IL4R (b 5 10.29, P 5 .002).
Higher expression levels of IL1R1, IL1RAP, and IL4R were associated with reduced FEV 1 /forced vital capacity ratio (b 5 20.11, 20 .08, and 20.10; P 5 .005, .07, and .05). Conclusion: IL-1 receptor appears to be a marker of neutrophilic inflammation and airflow obstruction in patients with asthma, who have a wide range of disease severity. Asthma is a chronic inflammatory disease with airway inflammation marked by increased numbers of eosinophils, basophils, mast cells, innate lymphoid cells, and CD4
1 T lymphocytes, which produce type 2 cytokines (IL-4, IL-5, and IL-13). In addition to type 2 cytokines, more severe asthma is often associated with an enhanced type 17 immune response, with increased IL-17A and IL-8 levels and airway neutrophil counts. [1] [2] [3] Although type 2 asthma responds generally to corticosteroid therapy, asthmatic patients with low type 2 markers might not respond well to current therapies and lack corticosteroid sensitivity. 4 Several new biological therapeutics targeting type 2 pathways have been developed and have been shown to improve outcomes in patients with a predominantly eosinophilic phenotype. However, there is a critical need for new therapies to treat low type 2 neutrophilic asthma.
Recent studies with large cohorts have aimed at phenotyping asthma in specific clusters. In the Severe Asthma Research Program (SARP) cohort, Moore et al 5 used clinical and physiologic characteristics, as well as sputum and blood eosinophil and neutrophil counts, to identify 4 clusters of asthmatic patients; 2 clusters that exhibited substantially higher sputum neutrophil counts also showed increased health care use, greater use of high-dose inhaled corticosteroids and oral and systemic corticosteroids, and reduced lung function. In addition, in this analysis approximately one third of both clusters with neutrophilic predominance also displayed high eosinophilia. In another report mixed granulocytic sputum samples (high neutrophil plus high eosinophil counts) were found in approximately 15% of the asthmatic population. 6 Therefore these studies indicate that the characteristics and biomarkers associated specifically with sputum neutrophils are difficult to identify.
The immune responses (type 2 and type 17) directing the accumulation of granulocytes (eosinophils and neutrophils) in the airway are complex. The type 2 and type 17 pathways can reciprocally downregulate each other, 7 and it has been shown recently that highly polarized type 2 and type 17 pathways did not coexist in asthmatic patients. 8 Conversely, it has been reported that IL-17A and IL-4 were coproduced in T lymphocytes, and these type 17/type 2 CD4
1 T lymphocytes are increased in asthmatic patients. 9 Also, airway dual-positive type 2/type 17 lymphocytes have been found in patients with severe asthma. 10 Studies by Liu et al 11 and Seys et al 12 have described the expression of high levels of either IL-4 or IL-5 along with IL-17 in asthmatic patients. [11] [12] [13] In addition, type 17 (IL-17A) and type 1 (IFN-g) lymphocytes are produced concomitantly in circulating blood cells from asthmatic patients with steroid resistance.
14 Surprisingly enough, studies analyzing the expression of the 3 pathways, type 1, type 2, and type 17, in asthmatic patients are lacking. Although levels of type 1 and type 2 cytokines and IL-17A protein have been concurrently measured in sputum samples in relation to airway remodeling, the association with inflammatory cells, particularly granulocytes, was not reported. 15 Multivariate statistical methods are needed to explore these complex associations between molecular immune markers and the types of airway granulocytes in asthmatic patients. In this study we used partial least squares (PLS) regression to analyze the relative expression of a group of genes characterizing the 3 T-cell immune response pathways (type 1, type 2, and type 17) in relation to cell differentials in sputum samples and pulmonary function in asthmatic patients. The objective was to identify gene predictors of specifically neutrophilic asthma and therefore to identify potential molecular pathways to target in the development of new treatments for neutrophilic asthma.
METHODS Subjects
The study protocol was approved by the University of Wisconsin-Madison Health Sciences Institutional Review Board. Informed written consent was obtained from subjects before participation. Induced sputum was obtained by using a standard method, as previously described, 16 from 48 subjects enrolled in SARP I and II at the University of Wisconsin. The subjects included in the current study are a subset of our recently published study, which included 56 subjects. 17 Of the 56 subjects, 7 did not have cell differentials performed on their sputum samples, and an additional subject was excluded because of low expression levels of the housekeeping gene (cycle threshold [Ct] > 29) in the sputum sample, whereas the average Ct level of the housekeeping gene b-glucuronidase gene (GUSB) for the 48 samples was less than 23. Current smokers and patients with more than 5 pack years of smoking history were ineligible to enroll in the study. All sputum induction visits were required to be at least 4 weeks after resolution of any asthma exacerbation. More detailed methods, including acquirement of subjects' characteristics and pulmonary function, were reported previously. 17 
RNA and reverse transcription quantitative PCR
Total RNA was prepared, and PCR was performed, as previously described. 17 Briefly, expression levels of mRNA were determined by using quantitative PCR with SYBR Green Master Mix (SABiosciences, Qiagen, Germantown, Md) or TaqMan primers and probe (Life Technologies, Grand Island, NY). The primers used in this study are shown Table E1 in this article's Online Repository at www.jacionline.org. Standard curves were performed, and efficiencies were determined for each set of primers. Efficiencies ranged between 91% and 99%. Data are expressed as minus DCt by using the reference gene GUSB, as described previously. 18 Expressions of 17 different genes in 48 sputum samples from 48 subjects were analyzed, and 18 of 816 observations were missing. Of the 18 missing observations, 7 did not reach sufficient quality, as determined by using the dissociation curves (3 for IL4, 2 for RORC, 1 for IFNG, and 1 for IL1RAP), and 11 lacked sufficient remaining sputum quantity to measure IL5 expression. More details are provided in the Methods section in this article's Online Repository at www.jacionline.org. reversibility, and forced vital capacity reversibility) to have zero mean and unit variance. Missing gene expression values (18/816 observations) were addressed by using a regularized iterative principal components analysis imputation algorithm with the R package missMDA, version 1.10. 21 The correlation matrix of genes, cells, and pulmonary functions was displayed by using the R package corrplot version 0.77 22 ; genes, cells, and pulmonary functions are each arranged by using the angular order of their correlation matrix eigenvectors, 23 which places similar variables adjacently. Because the genes measured are relatively numerous and highly correlated with one another, PLS (PLS/projection to latent structures) regression models 24, 25 were used to examine the relationships between gene expression and cell responses or lung function responses. Briefly, the goal of PLS regression is, given a set of numerous and/or correlated predictor variables, to extract a smaller set of orthogonal (uncorrelated) latent variables, called components, which best predict the response variable or variables. For the cell differential PLS model, a multiresponse (neutrophils, eosinophils, macrophages, and lymphocytes) model was fit with 17 genes as predictors, and a 3-component model was selected (see Fig E1 in this article's Online Repository at www.jacionline. org). To interpret the latent variables, the X (gene predictors) loadings and Y (cell responses) loadings for each latent variable were examined. Jackknife variance estimates were used to construct CIs for the regression coefficients for each gene. For pulmonary function responses, similar PLS regression models were fit, and 2-component models were selected in each case. The R package pls version 2.5-0 26 was used to fit and examine the PLS regression models. The optimal number of latent variables was chosen by using 8-fold cross-validation.
RESULTS
The subjects' characteristics are described in Table I . The 48 subjects had either severe (n 5 17) or nonsevere (n 5 31) asthma, as defined by the American Thoracic Society criteria. 27 Fourteen of 48 subjects were not using any corticosteroids, 16 were using low or medium doses of inhaled corticosteroids, 17 were taking high doses of inhaled corticosteroids, and 1 was a patient with severe asthma who took oral corticosteroids. Forty-three (90%) of the 48 subjects had an allergic reaction, as determined based on skin prick test responses to at least 1 of 12 common aeroallergens.
Expression levels of representative markers of type 1, type 2, and type 17 immune responses were measured by using RTquantitative PCR with 17 genes. Genes coding for cytokines, chemokine receptors, differentiating receptors, and transcription factors were used to define each of the 3 immune response groups. The type 2 immune response was analyzed by using IL4, IL5, IL13, CCR4, IL4R, IL1RL1 (a subunit of the IL-33 receptor), and GATA3; the type 17 response was analyzed by using IL17A, CCR6, IL1R1 (a subunit of the IL-1 receptor [IL-1R]), IL23R, and RORC; and the type 1 response was characterized by using IFNG, CXCR3, IL12RB2 (a subunit of the IL-12 receptor), and TBX21. IL1RAP, the coreceptor with IL1RL1 or IL1R1 required for intracellular signaling of both IL-1 and IL-33, might be included in both the type 17 and type 2 groups of genes. Fig 1 de- picts the correlations among genes, cell differentials and total white blood cells, and pulmonary function measures. There was a tendency for positive correlation among all genes, indicating that some subjects have generally higher expression than others across all markers independent of sample quality. There were also several genes that were highly correlated with each other. For instance, IL4, IL5, IL13, and IL1RL1 and IL17A, CCR6, and RORC formed 2 groups that might well define the type 2 or type 17 immune response, respectively.
Another interesting noticeable set of genes is IL1R1, IL1RAP, and IL4R. Although the strong association between IL1R1 and IL1RAP (the 2 subunits of the IL-1R) might be expected, the presence of IL4R in this small cluster was surprising. Interestingly, IL1RAP was more closely associated with its coreceptor IL1R1 (type 17) than with IL1RL1 (type 2). There was a negative correlation between PMN and macrophage percentages, as expected, and relatively strong correlations among spirometric measures.
Finally, Fig 1 shows correlations between genes, cells, and pulmonary function. Notable findings include (1) high correlations between eosinophil counts and IL4, IL5, IL13, and IL1RL1 expression; (2) high correlations between neutrophil counts and IL1R1, IL1RAP, and IL4R, among others; (3) correlations between pulmonary function and IL4, IL5, IL13, IL1RL1, IL1R1, IL1RAP, and IL4R; and (4) association of high eosinophil and neutrophil counts with worse pulmonary function.
To examine the relationship between expression of these 17 genes and sputum cell differentials, we fit a PLS regression model. A summary of the model fit is shown in Table E2 in this article's Online Repository at www.jacionline.org, and predicted versus actual cell differentials are shown in Fig E2 in this article' s Online Repository at www.jacionline.org. The 3 orthogonal latent variable components that form the PLS model account for 72% of the total variation across all 17 genes and explain 71% of eosinophil variation, 64% of neutrophil variation, and 68% of macrophage variation but only 26% of lymphocyte variation. Visual representations of the X loadings (gene predictors) and Y loadings (cell responses) for the 3 components of the PLS model are shown in Fig 2. The first component (Fig 2, A) explains 42% of the total variation across all 17 genes and might be interpreted as a latent variable representing subjects' general levels of gene expression. Higher expression in general tends to tilt a subject's balance in favor of increased eosinophil, increased neutrophil, and decreased macrophage counts.
The second component (Fig 2, B) orthogonal to the first component and thus independent of one's general tendency toward high J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 2 or low expression identifies genes with expression that is most strongly associated with eosinophil counts. High expression of IL4, IL5, IL13, and IL1RL1 (type 2) is associated with higher eosinophil counts, whereas increased expression of CXCR3 and IL12RB2 (type 1) and CCR6 and IL23R (type 17) favors lower eosinophil counts. The third component (Fig 2, C) , which is uncorrelated with both the first and second components, identifies genes with expression that is associated with increased neutrophil and decreased macrophage counts. High expression of IL1RAP, IL1R1, and IL4R corresponds to higher neutrophil and lower macrophage counts. Higher expression of genes, such as CCR4 and GATA3 (type 2) and TBX21, IL12RB2, CXCR3, and IFNG (type 1), is associated with reduced neutrophil and increased macrophage counts. The X and Y loadings for the second and third components are plotted together in Fig 2, D. The combined effects of these 3 components constitute the full PLS regression model. Fig 3 shows regression coefficients with approximate 95% CIs. IL4, IL5, IL13, and IL1RL1 expression levels are most strongly associated with higher eosinophil percentages. IL1R1, IL1RAP, and IL4R are most strongly associated with higher neutrophil and lower macrophage counts. To a lesser extent, CCR6 and IL17A appear to be associated with higher neutrophil counts and GATA3 and CCR4 with lower neutrophil counts. For lymphocytes, it appears that the genes associated with higher eosinophil counts also tend to associate with lymphocyte counts, although the estimated effects are more modest in size. These results can be contrasted with those obtained from ordinary multiple linear regression, as shown in Fig E3 in this article' s Online Repository at www.jacionline. org, where, because of the numerous and correlated predictors, the regression coefficients are unstable and have large SEs. Additional PLS regression models that examine the potential influence of asthma severity, age, and corticosteroid use on these relationships were also considered; the gene expression and cell differential relationships described above were not altered in these models (see Figs E5-E7 in this article's Online Repository at www. jacionline.org). Notably, older subjects tended toward higher eosinophil percentages, and patients with severe disease tended toward higher neutrophil percentages (see Fig E5) . Expression levels of the 17 genes were further analyzed in relation to pulmonary function measurements by using separate PLS regression models. Two-component models were selected in each case; summaries of the model fits are shown in Table E3 in this article's Online Repository at www.jacionline.org. Although the gene expression components in the cell differential model accounted for 71% and 64% of eosinophil and neutrophil variation, their explanatory power for pulmonary function is more modest, accounting for between 24% (residual volume/total lung capacity) and 34% (FEV 1 reversibility) of pulmonary function variation. Gene loading and pulmonary function on the first and second components of each model are shown in Fig E4 in this article' s Online Repository at www.jacionline.org. The first components of each model again might represent the general level of gene expression, with high expression favoring worse lung function, and the second components indicate genes with a relative balance favoring better or worse lung function. Fig 4 shows the regression coefficients for each model. Importantly, IL1RAP, IL4R, and IL1R1 (best predictors of neutrophilia) and IL4, IL5, IL13, and IL1RL1 (best predictors of eosinophilia) displayed the strongest associations with worse pulmonary outcomes across multiple measures.
DISCUSSION
In this study, using PLS regression analysis of inflammatory gene expression in sputum samples from asthmatic patients, we identified IL-1R as a predictor of neutrophilic asthma. Despite general expression level correlations among all 17 (type 1, type 2, and type 17) genes and unlike the results obtained when using an ordinary multiple linear regression model, the PLS analysis clearly distinguished the type 17 from type 2 immune responses in relation to sputum neutrophil or eosinophil percentages. The validity of this approach is supported by its confirmation of a strong association of the type 2 markers IL4, IL5, IL13, and IL1RL1 with eosinophil percentages, as would be anticipated. As expected from prior studies, 1,28 the neutrophil percentage was predicted by IL17A and CCR6, 2 major hallmarks of type 17 lymphocytes. 29, 30 However, our analyses showed that sputum neutrophilia in asthmatic patients was predicted more strongly by the 2 subunits of the functional receptor for IL-1, IL1R1 and IL1RAP.
IL1R1 has already been suggested as a potential therapeutic target in asthmatic patients, 31 probably because of allergic animal models in which the lack of IL-1R impairs the development of the type 2 immune airway response 32 and reduced airway eosinophilia and goblet cell hyperplasia. 33 The importance of the IL-1/IL-1R type 1 pathway in airway type 2 inflammation was further confirmed by using dual IL-1a and IL-1b or IL-1 receptor antagonist (IL-1RA) knockout mice. 34 In human subjects IL-1b levels are increased in both patients with atopic and those with nonatopic asthma, are increased at night in patients with nocturnal asthma, are associated with asthma symptoms, [35] [36] [37] and are J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 2 increased in bronchoalveolar lavage fluid and sputum samples from asthmatic patients. 38, 39 Recently, we have reported that IL1R1 and IL17A expression in sputum samples was positively correlated to systemic stress markers in asthmatic patients, 40 suggesting that severe and uncontrolled asthma symptoms often seen in patients with depression or anxiety 41 might be due in part to activation of the IL-1/IL-17 pathway. Interestingly, canakinumab is a humanized therapeutic IL-1b mAb that has been evaluated in phase 1/2 in patients with mild asthma in a randomized, doubleblind clinical study with good safety and anti-inflammatory outcomes. [42] [43] [44] However, no further therapeutic anti-IL-1 studies in asthmatic patients using canakinumab have been reported. In addition to canakinumab, 2 other drugs can block IL-1 action: anakinra, which is an IL-1RA protein, and the dimeric fusion protein rilonacept, which binds both IL-1R type 1 and IL-1RA protein. Interestingly, bronchoalveolar lavage fluid cells from asthmatic patients treated in vitro with anakinra displayed reduced numbers of IL-4 1 /IL-17 1 cells. 11 In a phase I clinical investigation anakinra was injected in subjects before an inhaled endotoxin challenge. In this study anakinra significantly reduced airway neutrophilia, and the drug was well tolerated. 45 However, no trials using these 2 drugs have been reported in asthmatic patients.
Inclusion of IL1R1 among the markers of type 17 lymphocytes in our study was driven by compelling evidence from the literature. IL-1R is present on type 17 lymphocytes, 29 and IL-1b alone can induce RORC production in naive CD4
1 T cells, leading to type 17 differentiation. 46 In addition, IL-1b increases IL-17 production by activated T H 17 1 memory T cells. 30 Supporting these findings, we showed that release of IL-1b by eosinophils was essential to enhance IL-17 production by activated CD45RO
1

CD4
1 T cells in vitro. 18 Of note, IL-1R upregulation on T cells can be reached by either a common g-chain cytokine (IL-7 or 15) plus TGF-b 47 or a cocktail closely similar to the IL-17-induced cocktail, including IL-2, IL-1b, IL-23, and TGF-b. 48 However, considering that previous studies have demonstrated increased airway neutrophil counts through IL-17-induced IL-8 production in the airway, 1,2,49,50 our data support that IL-1R is critical for neutrophil recruitment, possibly through IL-17 production. However, it is unclear why IL-1R was the molecule most associated with neutrophilia compared with the other type 17 markers (IL17A and CCR6).
Hastie et al 51 have reported increased expression and production of IL-1b in a group of asthmatic patients with high sputum neutrophilia. Although the IL1B expression level was not measured in the present study, induction of IL-1b can possibly lead to upregulation of IL-1R. 52, 53 The production and release of mature and functional IL-1b requires more than just IL1B expression and is largely dependent on inflammasome activation. 54, 55 IL-1b production and release generally depend on activation of both a Toll-like receptor and ATP, which consequently activate the inflammasome (NLRP3 and caspase-1). 56 Toll-like receptor ligands are microbial agents, whereas ATP originates from local cell death and signals through P2X7. 56 Interestingly, P2X7 pore activity has been linked to virus-induced asthma symptoms and asthma exacerbations. 57, 58 Furthermore, in agreement with the implication of the inflammasome in asthmatic patients, increased levels of both NLRP3 and IL-1b have been reported in patients with neutrophilic asthma. 59 Therefore excess inflammasome activity caused by viral or bacterial inflammation could be an upstream mechanism leading to the enhanced IL-1R production observed in our current study. A recent semibiased study identified a cluster of asthmatic patients with high sputum neutrophil counts. 60 The 39 genes characterizing this cluster did not contain the receptor for IL-1, yet these genes were associated with inflammasome and pattern recognition proteins. Analysis of inflammasome activity and its link to the IL-1 pathway in our asthmatic population will require further investigation.
In addition to airway neutrophilia, we also found that IL1R1 was one of the best predictors of worse pulmonary function. IL1R1 was associated with FEV 1 , airway obstruction (FEV 1 / forced vital capacity ratio), and air trapping (residual volume/total lung capacity), all indications of severe asthma. 61 The high predictive value of IL1R1 for these pulmonary functions is possibly due to its presence on both type 17 and type 2 lymphocytes. In fact, the possible presence of IL1R1 on type 2 lymphocytes and its implication in the development of type 2 airway inflammation 32,62 might explain why IL1R1 was not inversely associated with sputum eosinophil counts. IL-1R is also expressed on non-T cells, such as fibroblasts, epithelial cells, and airway smooth muscle cells. 53, 63, 64 Interestingly, IL-1b and IL-17 have synergistic functions on epithelial cells and airway smooth muscle cells, enhancing mucin production and neutrophil chemoattractant, and thus they might synergistically enhance airway obstruction. 65, 66 Even though sputum samples with high amounts of noninflammatory cells were excluded, we cannot rule out that epithelial cells are part of the IL1R1-expressing cells in our analysis. Some of the lymphocyte-characterizing genes used in the present study did not display the expected prediction value for neutrophils or eosinophils. For instance, IL4R, a common subunit receptor for IL-4 and IL-13, was highly correlated with IL1R1 and IL1RAP expression. IL4R is expressed on B and T lymphocytes and is upregulated by its ligand, IL-4, during Tlymphocyte differentiation into type 2 lymphocytes. 67, 68 Although a mechanistic explanation for the strong association between IL4R and IL-1R remains uncertain, recent highthroughput gene expression analyses have clustered IL4R with IL1R1 in viral infection models and in patients with urticaria or periodontitis. [69] [70] [71] Of note, the high allergy rate (90%) and relatively young age of our population are possible limitations of the current study. Indeed, some previous studies have demonstrated a higher percentage of patients with nonallergic asthma in older asthmatic populations. [72] [73] However, although an older and more neutrophilic population might have been underrepresented in our study, the analysis clearly distinguished eosinophilic and neutrophilic asthma in relation to the gene expression profile. We also note that although the 17 genes included in this study were carefully chosen to characterize the type 1, type 2, and type 17 immune response pathways, measuring a larger number of genes by using microarray or next-generation sequencing approaches will provide a fuller understanding of these relationships and is an important topic for further studies. In conclusion, using a multivariate statistical approach, we identified IL-1R as an important predictor of both neutrophilic asthma and worse pulmonary function. A treatment targeting the IL-1 pathway might be a reasonable consideration in patients with neutrophilic severe asthma.
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Key messages
d In sputum samples from asthmatic patients, expression levels for type 1, type 2, and type 17 markers are positively correlated with one another.
d A multivariate analysis identifies IL-1R as a strong predictor of sputum neutrophilia.
d The IL-1 pathway could contribute to neutrophilic asthma pathobiology.
